SON4PEM study: Sonlicromanol in post-COVID: A randomized, double-blind, placebo-controlled, phase II trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521866-92-01

Enrollment

Registered

2025-12-02

Start date

2025-12-12

Completion date

Unknown

Last updated

2025-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

long COVID

Brief summary

Fatigue symptoms measured at week 13 by the FAS

Detailed description

Secondary endpoints include improvement in various disease domains within long COVID on week 4, 8 and 13 using the SF-36 and the PROMIS cognitive function 8a score. In addition, physical improvement will be measured using the Repeated Handgrip Strength and the Amsterdam Cognition Scan on baseline and week 4, 8 and 13.

Interventions

DRUGSonlicromanol

DRUGSonlicromanol tablets Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Fatigue symptoms measured at week 13 by the FAS	—

Secondary

Measure	Time frame
Secondary endpoints include improvement in various disease domains within long COVID on week 4, 8 and 13 using the SF-36 and the PROMIS cognitive function 8a score. In addition, physical improvement will be measured using the Repeated Handgrip Strength and the Amsterdam Cognition Scan on baseline and week 4, 8 and 13.	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026